




Supplemental Tables and Figures




Supplemental Figure S1. Kinetics of bacterial clearance in respiratory tract. **(A)** Kinetics of CFU were determined in lungs of mice on 3, 4, 5, 6 and 7 days post challenge in groups immunized with omvPV-*bvg*(+)-Toh, omvPV-*bvg*(-)-Toh, omvPV-wtB1917, wcPV-Kh96/1 or saline (naive). Average and STDev are depicted. **(B)** Kinetics of colony forming units (CFU) were determined in lung, trachea and nasal wash on 3, 5 and 7 days post challenge of mice immunized with omvPV-wtB1917, omvPV-ΔBrkA, omvPV-ΔVag8, wcPV-Kh96/1 or saline (naive). Average of data per vaccine group per day is shown. Black dot represents concentration of challenge culture prior to challenge.



Supplemental Figure S2. Individual 2-Dimensional blots for immunoproteomic profiling omvPV-*bvg*(-)Toh and omvPV-*bvg*(+)Toh. Blots contain B1917 lysate (25 μ g) separated with 2D-electrophoresis on a isoelectric point range of 3 – 10 and molecular weight range of 260 – 3 kDa. Three individual blots per group were incubated with pooled serum from mice immunized with (A-C) omvPV-*bvg*(-)Toh or (D-F) omvPV-*bvg*(+)Toh in triplicate and spots visualized with an IR-800 labeled goat-anti-mouse IgG.



Supplemental Figure S3. Humoral responses on day 35 and day 56. On **A)** day 35, anti-Ptx, anti-Prn, anti-FHA, anti-Fim2/3, anti-OMV, anti-BrkA and anti-Vag8 IgG responses, **B)** day 56, anti-Ptx, anti-Prn, anti-FHA and anti-Fim2/3 IgG responses were determined in serum of naive mice or mice vaccinated with omvPV-wtB1917, omvPV-ΔBrkA, omvPV-ΔVag8 or wcPV-Kh96/1. Fluorescence intensity (FI) values are depicted on a $^{10}\log$ scale axis. Significant differences compared to the naive mice are indicated as # $p \leq 0.05$, ## $p \leq 0.01$ and ### $p \leq 0.001$ and actual P-values are shown in **Supplemental Table S2**. Significant differences between experimental groups is depicted with a line between both groups and * $p \leq 0.05$, ** $p \leq 0.01$ and *** $p \leq 0.001$.



Supplemental Figure S4. Humoral subclass responses. Distribution of IgG subclass anti-OMV, anti-BrkA, anti-Vag8, anti-Prn, anti-FHA, anti-Fim2/3, anti-Ptx responses in naive mice or mice vaccinated with omvPV-wtB1917, omvPV-ΔBrkA, omvPV-ΔVag8 or wcPV-Kh96/1. Fluorescence intensity (FI) values are depicted on a ¹⁰log scale axis. Significant differences compared to the naive mice are indicated as # $p \leq 0.05$, # # $p \leq 0.01$ and # # # $p \leq 0.001$ and actual P-values are shown in **Supplemental Table S2**. Significant differences between experimental groups is depicted with a line between both groups and * $p \leq 0.05$, ** $p \leq 0.01$ and *** $p \leq 0.001$. .

Supplemental Table S1. Raw data immunoproteomic profiling with 2-dimensional Western blotting (2DEWB).

Cluster	Protein ID	Accession number	mW (kDa)	pI	Coverage (%)	High confident identified peptides	gray value omvPV- <i>bvg</i> (-)Toh 1	gray value omvPV- <i>bvg</i> (-)Toh 2	gray value omvPV- <i>bvg</i> (-)Toh 3	Average gray value omvPV- <i>bvg</i> (-)Toh 1-3	gray value omvPV- <i>bvg</i> (+)Toh 1	gray value omvPV- <i>bvg</i> (+)Toh 2	gray value omvPV- <i>bvg</i> (+)Toh 3	Average gray value omvPV- <i>bvg</i> (+)Toh 1-3
I	CarB	Q7VY97	118.1	5.4	40	43	0.0617	0.0343	0.0667	0.0542	0.0059	0.0026	0.0185	0.0090
	AZ26-0755	A0A171K0C9	32	7.2	80	12	0.0101	0.0671	0.0352	0.0375	0.0055	0.0160	0.0084	0.0099
II	U1						1.0043	0.3678	1.6629	1.0117	0.0567	0.2296	0.0602	0.1155
	groL	P48210	57.4	5.2	86	60	0.4980	0.5649	0.6410	0.5679	0.1892	0.1237	0.3071	0.2067
III	groL 2	P48210	57.4	5.2	40	21	0.1199	0.0651	0.1496	0.1115	0.0505	0.0593	0.1027	0.0708
	U2						4.4664	2.6600	8.0628	5.0630	2.7591	7.0814	3.3281	4.3895
	U3						0.7152	0.8675	2.4633	1.3487	1.0047	2.9294	0.4898	1.4746
	U4						0.0002	0.0650	0.2914	0.1188	0.0117	0.1298	0.0878	0.0764
	odhB	Q7VZ17	41.8	5.5	75	20	0.0158	0.0164	0.0145	0.0156	0.0082	0.0112	0.0114	0.0102
	TufI	Q7TT91	41.8	5.5	78	24	0.0190	0.0117	0.0171	0.0160	0.0097	0.0262	0.0172	0.0177
	U5						0.1553	0.1423	0.2512	0.1829	0.3146	2.2625	0.3254	0.9675
IV	Vag8	Q79GN7	94.8	6.8	64	42	0.0119	0.0085	0.0276	0.0160	0.0326	0.6159	0.1126	0.2537
	U6						0.0200	0.0004	0.0152	0.0119	0.0220	0.1092	0.0278	0.0530
	rpsA	Q7VZG0	63.0	5.2	68	38	0.0345	0.0072	0.0051	0.0156	0.0280	0.0869	0.0413	0.0521
V	Brka	Q45340	103.3	7.1	47	30	0.0105	0.0080	0.0092	0.0092	0.0995	0.3554	0.2925	0.2491
	Brka 2	Q45340	103.3	7.1	29	17	0.0121	0.0058	0.0040	0.0073	0.0263	0.2899	0.1882	0.1681
	Brka 3	Q45340	103.3	7.1	29	16	0.0022	0.0081	0.0042	0.0048	0.0205	0.1543	0.1343	0.1030
	Prn	P14283	93.4	9.2	43	25	0.0107	0.0045	0.0043	0.0065	0.0158	0.0942	0.0359	0.0486
	U7						0.0018	0.0006	0.0003	0.0009	0.0160	0.0397	0.2239	0.0932
	bteA	A0A171JW44	68.6	5.3	88	37	0.0079	0.0030	0.0049	0.0052	0.0208	0.0510	0.0290	0.0336
	odhL	Q7VZ16	62.3	6.0	81	37	0.0083	0.0023	0.0057	0.0054	0.0210	0.1061	0.0210	0.0503
	dadA	Q7VXF6	45.9	7.4	47	14	0.0031	0.0068	0.0002	0.0033	0.0032	0.0173	0.0192	0.0132
	Ahcy	Q7VUL8	51.6	6.1	57	24	0.0105	0.0073	0.0078	0.0085	0.0170	0.0065	0.0274	0.0169
	aceF	Q7VZC4	57.2	5.9	60	24	0.0042	0.0037	0.0037	0.0037	0.0208	0.0086	0.0121	0.0139

Supplemental Table S2. Statistical significance of humoral responses.

IgG total day 35	Ptx	Prn	FHA	Fim2/3	OMV	BrkA	Vag8
Naive vs. omvPV-wtB1917	ns ¹	ns	ns	ns	***2	***	***
Naive vs. omvPV-ΔBrkA	ns	ns	ns	ns	***	Ns	***
Naive vs. omvPV-ΔVag8	ns	ns	ns	ns	***	***	ns
IgG total day 56	Ptx	Prn	FHA	Fim2/3	OMV	BrkA	Vag8
Naive vs. omvPV-wtB1917	ns	ns	ns	ns	***	*	*
Naive vs. omvPV-ΔBrkA	ns	*	ns	ns	***	ns	***
Naive vs. omvPV-ΔVag8	ns	ns	ns	ns	*	***	ns
Naive vs. wcPV-Kh96/1	**	ns	***	ns	*	*	**
IgG1	Ptx	Prn	FHA	Fim2/3	OMV	BrkA	Vag8
Naive vs. omvPV-wtB1917	ns	ns	ns	ns	ns	*	*
Naive vs. omvPV-ΔBrkA	ns	*	ns	ns	**	ns	**
Naive vs. omvPV-ΔVag8	ns	ns	ns	ns	ns	***	ns
Naive vs. wcPV-Kh96/1	**	ns	***	*	***	***	***
IgG2a	Ptx	Prn	FHA	Fim2/3	OMV	BrkA	Vag8
Naive vs. omvPV-wtB1917	N.A. ³	ns	ns	ns	***	**	***
Naive vs. omvPV-ΔBrkA	N.A.	ns	ns	ns	***	ns	***
Naive vs. omvPV-ΔVag8	N.A.	ns	ns	ns	ns	***	ns
Naive vs. wcPV-Kh96/1	N.A.	ns	***	ns	**	ns	ns
IgG2b	Ptx	Prn	FHA	Fim2/3	OMV	BrkA	Vag8
Naive vs. omvPV-wtB1917	N.A.	ns	ns	ns	*	*	**
Naive vs. omvPV-ΔBrkA	N.A.	ns	ns	ns	**	ns	***
Naive vs. omvPV-ΔVag8	N.A.	ns	ns	ns	*	***	ns
Naive vs. wcPV-Kh96/1	N.A.	ns	***	ns	**	ns	ns
IgG3	Ptx	Prn	FHA	Fim2/3	OMV	BrkA	Vag8
Naive vs. omvPV-wtB1917	N.A.	N.A.	***	ns	**	*	**
Naive vs. omvPV-ΔBrkA	N.A.	N.A.	***	ns	***	ns	***
Naive vs. omvPV-ΔVag8	N.A.	N.A.	*	ns	***	***	ns
Naive vs. wcPV-Kh96/1	N.A.	N.A.	ns	ns	*	ns	ns

¹ ns = not significant; ² * p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 0.001; ³ N.A. = not applicable

Supplemental Table S3. Statistical significance of B-cell responses.

Plasma B-cells (d35)	OMV	BrkA	Vag8
Naive vs. omvPV-wtB1917	*** ¹	**	***
Naive vs. omvPV-ΔBrkA	**	ns ²	***
Naive vs. omvPV-ΔVag8	**	***	ns
Memory B-cells (d56)	OMV	BrkA	Vag8
Naive vs. omvPV-wtB1917	**	ns	ns
Naive vs. omvPV-ΔBrkA	**	ns	ns
Naive vs. omvPV-ΔVag8	ns	ns	ns
Naive vs. wcPV-Kh96/1	ns	ns	ns

¹ ** p ≤ 0.01 and *** p ≤ 0.001; ² ns = not significant.

Supplemental Table S4. Statistical significance of T-helper responses.

OMV stimulation	IFNγ	IL-10	IL-13	IL-17A	IL-4	IL-5	TNFα
Naive vs. omvPV-wtB1917	** ¹	*	**	**	**	***	N.A. ²
Naive vs. omvPV-ΔBrkA	**	***	***	**	**	*	N.A.
Naive vs. omvPV-ΔVag8	***	**	**	**	***	ns	N.A.
Naive vs. wcPV-Kh96/1	ns ³	ns	ns	ns	ns	**	N.A.
BrkA stimulation	IFNγ	IL-10	IL-13	IL-17A	IL-4	IL-5	TNFα
Naive vs. omvPV-wtB1917	**	ns	***	***	**	**	*
Naive vs. omvPV-ΔBrkA	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.
Naive vs. omvPV-ΔVag8	***	***	***	***	***	***	***
Naive vs. wcPV-Kh96/1	ns	ns	ns	ns	ns	ns	**
Vag8 stimulation	IFNγ	IL-10	IL-13	IL-17A	IL-4	IL-5	TNFα
Naive vs. omvPV-wtB1917	***	*	***	**	***	**	*
Naive vs. omvPV-ΔBrkA	***	***	***	***	***	***	**
Naive vs. omvPV-ΔVag8	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.
Naive vs. wcPV-Kh96/1	ns	ns	ns	ns	ns	ns	**

¹ * p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 0.001; ² N.A. = not applicable; ³ ns = not significant.